Jeffrey Eisele, Chief Development Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 14,756 shares at $63.69 ($940K) on 2024-01-23, disclosed to the SEC on 2024-01-24.
Scheduled sale ($940k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $63.69 | 7,378 | $470K | 50.0% |
| 2 | $63.69 | 7,378 | $470K | 50.0% |
| Total | $63.69 avg | 14,756 | $940K | 100% |
| Filing → |
| APLS | SELL | 2025-01-14 | $8K | — | Filing → |
| APLS | SELL | 2024-12-27 | $2K | — | Filing → |
| APLS | SELL | 2024-01-31 | $145K | — | Filing → |